Substituted amides

Details Substituted amides Substituted amides

2008-01-14

2009-08-18

Zucker, Paul A (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S123000, C564S161000, C564S168000, C514S345000

Reexamination Certificate

active

07576239

ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

REFERENCES:
patent: 4360519 (1982-11-01), White et al.
patent: 5281611 (1994-01-01), Sawyer et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6359175 (2002-03-01), Philippe et al.
patent: 7348456 (2008-03-01), Lin et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2004/0058820 (2004-03-01), Hagmann et al.
patent: 2004/0224962 (2004-11-01), Coe et al.
patent: 2004/0224963 (2004-11-01), Coe et al.
patent: 2004/0248956 (2004-12-01), Hagmann et al.
patent: 2005/0137159 (2005-06-01), Bab et al.
patent: 2005/0154202 (2005-07-01), Hagmann et al.
patent: 2005/0171161 (2005-08-01), Fong et al.
patent: 2005/0182103 (2005-08-01), Finke et al.
patent: 2006/0106071 (2006-05-01), Lin et al.
patent: 899556 (1962-06-01), None
patent: 1172346 (1969-11-01), None
patent: WO 98/33765 (1998-08-01), None
patent: WO 98/56754 (1998-12-01), None
patent: WO 01/09120 (2001-02-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/009005 (2003-01-01), None
patent: WO 03/063781 (2003-08-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 03/077847 (2003-09-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/082833 (2003-10-01), None
patent: WO 03/086288 (2003-10-01), None
patent: WO 03/087037 (2003-10-01), None
patent: WO 2004/012671 (2004-02-01), None
patent: WO 2004/029204 (2004-04-01), None
patent: WO 2004/048317 (2004-06-01), None
patent: WO2004/058145 (2004-07-01), None
patent: WO 2005/000301 (2005-01-01), None
patent: WO 2005/000809 (2005-01-01), None
patent: WO 2005/009479 (2005-02-01), None
patent: WO 2005/020988 (2005-03-01), None
patent: WO 2005/020992 (2005-03-01), None
patent: WO 2005/027837 (2005-03-01), None
patent: WO 2005/039550 (2005-05-01), None
patent: WO 2005/043327 (2005-05-01), None
Finkelstein et al. Journal of Medicinal Chemistry, 1971, 14, p. 584-588.
Lange et al., Drug Discovery Today, vol. 10 (2005), pp. 693-702, “Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists”.
Petitet et al., Emerging Drugs, vol. 3 (1998), pp. 39-53, “The therapeutic applications of cannabinoid agonists and antagonists”.
Di Marzo et al., Emerging Therapeutic Targets, vol. 5 (2001), pp. 241-265, “Endocannabinoids Part I: Molecular basis fo endocannabinoid formation, action and inactivation and development of selectie inhibitors”.
Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, “Recent advances in cannabinoid receptor agonists and antagonists”.
Adam et al., Exp. Opin. Ther. Patents, vol. 12 2002), pp. 1475-1489, “Recent advances in the cannabinoids”.
Barth, Exp. Opin. Ther. Patents, vol. 8 (1998), pp. 301-313, “Cannabinoid receptor agonists and antagonists”.
Ito et al., Chem. Pharm. Bull., vol. 20 (1972), pp. 1762-1767, “Catalytic hydrogenation of tetrahydro-4H-1,3-oxazin-4-ones and 4-oxazolidinones”.
Ishiwata et al., Yakugaku Zashi, vol. 71 (1951), pp. 1272-1274, “Studies on the syntheses of isoquinoline derivatives”.
Grundy et al., Exp. Opin. Investig. Drugs, vol. 11 (2002), pp. 1365-1374, “The therapeutic potential of the cannabinoids in neuroprotection”.
Pines et al., J. Med. Chem., vol. 10 (1967), pp. 725-728, “The stereochemistry of 2,3-diphenyl-1-methylpropylamine”.
Schultz et al., J. Med. Chem., vol. 10 (1967), pp. 717-724, “Maleamic acids that affect plasma cholesterol and penicillin excretion”.
Le Foll et al., J. Pharmacol. Exp. Ther., vol. 312 (2005), pp. 875-883, “Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence”.
Konosu et al., Chem. Pharm. Bull., vol. 39 (1991), pp. 2581-2589, “Triazole antifungals . . . ”.
Novak et al., Pestic. Sci., vol. 49 (1997), pp. 85-89, “Preparation of novel hexythiazox anaogues”.
Canonica et al., Gazzetta Chimica Italiana, vol. 84 (1954), pp. 175-186, “The action of Grignard reagents on α-diazo ketones”.
Database HCAPLUS, Hagmann et al., XP002513691, No. 2003:796415 (2003), “Preparation of spirocyclic carboxamides as cannabinoid receptor modulators”.
Database HCAPLUS, Hagmann et al., XP002513692, No. 2003:837028 (2003), “Preparation of substituted arylamides as cannabinoid-1 receptor antagonists and/or inverse agonists for use as psychotropic drugs”.

Affiliated with

Also associated with

Rating

Substituted amides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted amides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4090729